Published January 30, 2013 | Version v1
Journal article

Periodical assessment of genitourinary and gastrointestinal toxicity in patients who underwent prostate low-dose-rate brachytherapy

  • 1. Department of Urology, Nara Medical University, 840 Shijo-cho, Kashihara, Nara, 634-8522 (Japan)
  • 2. Departments of Urology, Nara Medical University, Kashihara (Japan)
  • 3. Department of Radiation Oncology, Nara Medical University, Kashihara (Japan)
  • 4. Department of Pathology, Nara Medical University, Kashihara (Japan)

Description

To compare the periodical incidence rates of genitourinary (GU) and gastrointestinal (GI) toxicity in patients who underwent prostate low-dose-rate brachytherapy between the monotherapy group (seed implantation alone) and the boost group (in combination with external beam radiation therapy (EBRT)). A total of 218 patients with a median follow-up of 42.5 months were enrolled. The patients were divided into 2 groups by treatment modality, namely, the monotherapy group (155 patients) and the boost group (63 patients). The periodical incidence rates of GU and GI toxicity were separately evaluated and compared between the monotherapy group and the boost group using the National Cancer Institute - Common Terminology Criteria for Adverse Events, version 3.0. To elucidate an independent factor among clinical and postdosimetric parameters to predict grade 2 or higher GU and GI toxicity in the acute and late phases, univariate and multivariate logistic regression analyses were carried out. Of all patients, 78.0% showed acute GU toxicity, and 7.8% showed acute GI toxicity, while 63.8% showed late GU toxicity, and 21.1% showed late GI toxicity. The incidence rates of late GU and GI toxicity were significantly higher in the boost group. Multivariate analysis showed that the International Prostate Symptom Score (IPSS) before seed implantation was a significant parameter to predict acute GU toxicity, while there were no significant predictive parameters for acute GI toxicity. On the other hand, combination with EBRT was a significant predictive parameter for late GU toxicity, and rectal volume (mL) receiving 100% of the prescribed dose (R100) was a significant predictive parameter for late GI toxicity. The boost group showed higher incidence rates of both GU and GI toxicity. Higher IPSS before seed implantation, combination with EBRT and a higher R100 were significant predictors for acute GU, late GU and late GI toxicity

Availability note (English)

Available from http://dx.doi.org/10.1186/1748-717X-8-25; Available from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3570431

Additional details

Publishing Information

Journal Title
Radiation Oncology (Online)
Journal Volume
8
Journal Page Range
p. 25
ISSN
1748-717X

INIS

Country of Publication
United Kingdom
Country of Input or Organization
International Atomic Energy Agency (IAEA)
INIS RN
47062047
Subject category
S62: RADIOLOGY AND NUCLEAR MEDICINE;
Descriptors DEI
BRACHYTHERAPY; EXTERNAL BEAM RADIATION THERAPY; MULTIVARIATE ANALYSIS; NEOPLASMS; PATIENTS; PERIODICITY; PROSTATE; REGRESSION ANALYSIS; SEEDS; TOXICITY
Descriptors DEC
BODY; DISEASES; GLANDS; MALE GENITALS; MATHEMATICS; MEDICINE; NUCLEAR MEDICINE; ORGANS; RADIOLOGY; RADIOTHERAPY; STATISTICS; THERAPY; VARIATIONS

Optional Information

Copyright
Copyright (c)2013 Tanaka et al.
Notes
PMCID: PMC3570431; PUBLISHER-ID: 1748-717X-8-25; PMID: 23363647; OAI: oai:pubmedcentral.nih.gov:3570431; licensee BioMed Central Ltd.